BlackRock Amends Kura Oncology Stake, Signals Portfolio Adjustment
Ticker: KURA · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Kura Oncology stake, signaling a portfolio rebalance.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership of Kura Oncology Inc. common stock as of December 31, 2023. This filing, Amendment No. 5, updates BlackRock's previous disclosures regarding its passive investment in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or investment strategy, potentially influencing other investors' perceptions of Kura Oncology's stock.
Why It Matters
Changes in large institutional holdings like BlackRock's can influence market sentiment and stock price, as other investors often follow the lead of major players.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate, significant risk to Kura Oncology.
Analyst Insight
Investors should monitor subsequent filings from BlackRock and other major institutions for Kura Oncology to identify any emerging trends in institutional ownership, but this specific filing is a routine update.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Kura Oncology, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 5 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 5)'.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What company's securities are the subject of this filing?
The securities of Kura Oncology, Inc. are the subject of this filing, as indicated by 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Kura Oncology, Inc.' and 'Name of Issuer) Kura Oncology Inc'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as stated under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Kura Oncology, Inc. (KURA).